Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Announcement on Early Termination of GV-971 Global Multi-Center Phase III Clinical Trial
Details : GV-971 (sodium oligomannate), demonstrated significant efficacy in improving cognition with sustained improvement across all observation periods of a 36-week trial. GV-971 was safe and well-tolerated.
Product Name : GV-971
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 13, 2022
Lead Product(s) : Sodium Oligomannate
Therapeutic Area : Neurology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Green Valley to Start US Trials of Algae-Based Alzheimer’s Drug
Details : Green Valley Pharma’s scientists have suggested that GV-971 may work by altering the balance of microorganisms in the GI tract that contribute to inflammation in the central nervous system.
Product Name : GV-971
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 27, 2020
Lead Product(s) : Sodium Oligomannate
Therapeutic Area : Neurology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Green Valley’s treatment, known as GV-971, relies on a type of sugar extracted from brown algae. The drug aims to treat imbalances in the microbiome of the gut, which researchers believe may cause inflammation in the brain and may lead to Alzheimer’s...
Product Name : GV-971
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 11, 2020
Reset All
